N-methyl-D-aspartate receptor (NMDAR) - Phencyclidine (PCP) binding site (NMDAR PCP site)

The N-methyl-D-aspartate receptor (NMDAR) Phencyclidine (PCP) binding site is a specialized pharmacological pocket located deep within the ion-conducting pore of the NMDAR, a heterotetrameric ligand-gated ion channel (StatPearls, NBK470357). This site is unique because it is only accessible to ligands when the channel is in an open state, a property known as use-dependent or uncompetitive antagonism (NCBI, PMC3001304). Biologically, the NMDAR is essential for synaptic plasticity, long-term potentiation, and excitatory signaling in the central nervous system. Dysregulation of NMDAR activity is implicated in various pathologies, including Alzheimer's disease, where chronic overactivation leads to excitotoxic cell death, and major depressive disorder, where rapid-acting antidepressants like ketamine target this site. Drugs such as memantine utilize low-affinity blockade of the PCP site to provide neuroprotection with minimal side effects, whereas high-affinity blockers like PCP or MK-801 induce significant dissociative and psychotomimetic symptoms (PubMed, 29958300). Consequently, the PCP site remains a critical focus for developing treatments for treatment-resistant depression and neurodegenerative disorders while managing risks of cognitive and psychiatric adverse events.

Other names

NMDA receptor channel poreDizocilpine binding siteMK-801 binding siteUncompetitive antagonist siteNMDAR open-channel blocker site

Uncompetitive antagonism characterized by pore blockade; the ligand binds to a site within the ion channel that is only accessible when the channel is open (use-dependence), thereby inhibiting ion conductance (primarily Ca2+ and Na+) without competing with the endogenous agonists glutamate and glycine (NCBI, PMC3001304; Nature, 10.1038/nature13548).